Is Arbutus Biopharma Corporation (NASDAQ:ABUS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arbutus Biopharma Corporation at current levels.
A functional cure for Hep B is the prize, and Arbutus owns the patents plus the lead RNAi drug.
Where ABUS is headed
Arbutus sits on two assets that don't usually share a balance sheet. One is imdusiran, an RNAi therapeutic that knocks down Hepatitis B surface antigen and is showing functional cure rates in combination regimens that the field hasn't seen before. The other is a portfolio of LNP delivery patents that helped underwrite the Moderna and Pfizer COVID vaccines, with active litigation that has already produced one settlement (Moderna, March 2025) and another case (Pfizer/BioNTech) heading toward trial. The market is treating Arbutus as a $900M clinical biotech. It's actually a binary call on chronic HBV plus a structured legal payout.
Read the full Compass Direction on ABUS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.25).
See the full ABUS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Arbutus Biopharma Corporation (NASDAQ:ABUS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arbutus Biopharma Corporation at current levels. A functional cure for Hep B is the prize, and Arbutus owns the patents plus the lead RNAi drug.
What is ABUS's Compass Score?
Arbutus Biopharma Corporation scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ABUS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ABUS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.